PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Gauges a company's environmental, social, and governance practices.
56.75
ESG score 90-95% of Biotechnology median of 61.16. John Neff would demand higher returns to compensate for below-average ESG risk management.
54.36
Environmental score near Biotechnology median of 56.29. David Dodd would investigate if industry-standard environmental practices adequately address climate risks.
57.83
Social score 80-90% of Biotechnology median of 64.53. Martin Whitman would look for hidden social liabilities and reputational risks.
58.05
Governance score 90-95% of Biotechnology median of 62.75. John Neff would demand higher returns to compensate for below-average governance oversight.